+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Analysis of circulating mirnas in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis



Analysis of circulating mirnas in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis



Atherosclerosis 263: E278-E278




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046715181

Download citation: RISBibTeXText

PMID: 29366049

DOI: 10.1016/j.atherosclerosis.2017.06.897


Related references

Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis. Atherosclerosis. Supplements 30: 128-134, 2017

Regression of atherosclerosis in patients with familial hypercholesterolaemia under LDL-apheresis. Progress in Clinical and Biological Research 255: 317-326, 1988

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. Atherosclerosis 240(2): 408-414, 2015

Long-term efficacy of lipoprotein apheresis in the management of familial hypercholesterolaemia: Application of two different apheresis techniques in childhood. Transfusion and Apheresis Science 54(2): 282-288, 2016

Effects of LDL apheresis on blood rheology in two patients with homozygous familial hypercholesterolaemia. Blood Purification 15(3): 182-187, 1997

Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. Bmc Cancer 17(1): 730, 2017

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet. Diabetes and Endocrinology 5(4): 280-290, 2017

Prospective cross-over comparisons of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia. European Journal of Clinical Investigation 26(11): 1033-1038, 1996

Prospective randomised cross-over comparison of three different LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Kidney & Blood Pressure Research 23(3-5): 304, 2000

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. European Heart Journal (): -, 2016

Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis 151(2): 493-499, 2000

Upregulation of cholesterol synthesis by LDL apheresis Contrasting effects in familial hypercholesterolaemia and familial combined hyperlipidaemia. Clinical Science 88(2): 17P, 1995

Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. Journal of Internal Medicine 245(1): 47-55, 1999

Low-density lipoprotein apheresis improves regional myocardial blood flow in patients with familial hypercholesterolaemia and extensive coronary artery disease. European Heart Journal 16(ABSTR Suppl. ): 463, 1995

Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Annals of Clinical Biochemistry 46(Pt 1): 24-32, 2008